100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44AI120388
Award Date
7/22/16
Completion Date
9/30/25
Dollars Obligated
$9.8M
Overview
Activity
17
Transactions
17
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Hawaii Biotech, Inc. (ECJKEEFL4L51)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Hawaii, USA
Update #1
Update #2
CHIKUNGUNYA RECOMBINANT SUBUNIT VACCINE
Posted 4/17/20
5
1
2
3
4
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
CHIKUNGUNYA RECOMBINANT SUBUNIT VACCINE - 7. PROJECT SUMMARY/ABSTRACT CHIKUNGUNYA VIRUS (CHIKV) IS AN ALPHAVIRUS OF THE TOGAVIRIDAE FAMILY THAT CAUSES FEVER, RASH, AND ARTHRALGIA IN HUMANS, LEADING TO DEBILITATING ILLNESS AND POOR QUALITY OF LIFE. IN THE PAST 20 YEARS, CHIKV HAS GREATLY EXPANDED ITS GEOGRAPHIC DISTRIBUTION IN PART DUE TO CLIMATE CHANGES AS WELL AS ITS ADAPTATION TO AEDES ALBOPICTUS MOSQUITOES AND REMAINS A GLOBAL HEALTH THREAT DUE TO ITS HIGH RATE OF INFECTIVITY AND THE SEVERITY OF DISEASE IT CAUSES. ESTIMATES INDICATE THAT OVER 1.3 BILLION PEOPLE RESIDE IN AREAS AT RISK FOR CHIKV TRANSMISSION, WITH OVER 114,181 CASES AND 43 DEATHS REPORTED TO DATE IN 2023 ALONE. DESPITE CHIKV'S CLASSIFICATION AS A CATEGORY C PRIORITY PATHOGEN AND ITS RECENT IDENTIFICATION AS A PROTOTYPE PATHOGEN FOR NIAID'S PLAN FOR PANDEMIC PREPAREDNESS, THERE ARE CURRENTLY NO LICENSED VACCINES OR THERAPEUTICS TO PROTECT AGAINST CHIKV INFECTION. WHILE A FEW VACCINE CANDIDATES HAVE PROGRESSED TO ADVANCED STAGES OF DEVELOPMENT, MANUFACTURING CHALLENGES EXIST FOR COMPLEX VACCINE COMPOSITIONS FOR ENVELOPED VIRUSES. THIS IS COMPOUNDED BY AN INCOMPLETE UNDERSTANDING OF VIRALLY-INDUCED CHRONIC CHIKV DISEASE MECHANISMS THAT CAN INTRODUCE ADVERSE EVENT RISKS, ESPECIALLY FOR REPLICATION-COMPETENT VACCINES. ALTERNATE VACCINES UTILIZING METHODS THAT CAN OFFER BETTER SAFETY PROFILES AS WELL AS BENEFITS IN MANUFACTURING ARE WARRANTED. WE HAVE DEVELOPED A PROMISING RECOMBINANT SUBUNIT CHIKV VACCINE THAT INDUCES HIGH LEVELS OF NEUTRALIZING ANTIBODIES, PREVENTS VIRAL REPLICATION IN IMMUNOCOMPETENT MICE AND PROTECTS IMMUNOCOMPROMISED MICE FROM LETHAL CHALLENGE. THE ROLE OF ANTIBODIES IN PROTECTION WAS DEMONSTRATED IN A PASSIVE TRANSFER STUDY WHERE IMMUNE SERA WAS INJECTED INTO NAIVE IMMUNOCOMPROMISED MICE AND FULL PROTECTION WAS ACHIEVED AFTER LETHAL VIRUS CHALLENGE. THE OVERALL GOAL OF THE CURRENT PHASE IIB RENEWAL RESEARCH IS TO SUPPORT PRECLINICAL EFFORTS TO FURTHER ADVANCE THE CHIKV E2/E1 RECOMBINANT SUBUNIT VACCINE CANDIDATE FORMULATED WITH THE NEXT-GENERATION ADJUVANT SLA-LSQ. THESE EFFORTS WILL ENABLE HUMAN CLINICAL TRIAL EVALUATION AND FURTHER THE POTENTIAL FOR COMMERCIALIZATION. THE PROPOSED RESEARCH AIMS TO 1) EVALUATE THE E2/E1 VACCINE IN CHRONIC DISEASE AND DURABILITY STUDIES; 2) PREPARE CGMP LOTS OF E2/E1 VACCINE ANTIGEN; 3) SUBMIT A PRE-IND PACKAGE TO FDA FOR REVIEW AND CONDUCT A RABBIT TOXICOLOGY STUDY; AND 4) PREPARE AND SUBMIT IND TO THE FDA. COMPLETION OF THE PROPOSED WORK WILL PROMOTE THE CLINICAL ADVANCEMENT OF A SAFE AND STABLE VACCINE ALTERNATIVE USING AN ESTABLISHED RECOMBINANT PROTEIN MANUFACTURING PLATFORM THAT CAN COMBAT THE SIGNIFICANT DISEASE THREAT POSED BY CHIKV.
$0
8/22/25
Not listed
CHIKUNGUNYA RECOMBINANT SUBUNIT VACCINE - 7. PROJECT SUMMARY/ABSTRACT CHIKUNGUNYA VIRUS (CHIKV) IS AN ALPHAVIRUS OF THE TOGAVIRIDAE FAMILY THAT CAUSES FEVER, RASH, AND ARTHRALGIA IN HUMANS, LEADING TO DEBILITATING ILLNESS AND POOR QUALITY OF LIFE. IN THE PAST 20 YEARS, CHIKV HAS GREATLY EXPANDED ITS GEOGRAPHIC DISTRIBUTION IN PART DUE TO CLIMATE CHANGES AS WELL AS ITS ADAPTATION TO AEDES ALBOPICTUS MOSQUITOES AND REMAINS A GLOBAL HEALTH THREAT DUE TO ITS HIGH RATE OF INFECTIVITY AND THE SEVERITY OF DISEASE IT CAUSES. ESTIMATES INDICATE THAT OVER 1.3 BILLION PEOPLE RESIDE IN AREAS AT RISK FOR CHIKV TRANSMISSION, WITH OVER 114,181 CASES AND 43 DEATHS REPORTED TO DATE IN 2023 ALONE. DESPITE CHIKV'S CLASSIFICATION AS A CATEGORY C PRIORITY PATHOGEN AND ITS RECENT IDENTIFICATION AS A PROTOTYPE PATHOGEN FOR NIAID'S PLAN FOR PANDEMIC PREPAREDNESS, THERE ARE CURRENTLY NO LICENSED VACCINES OR THERAPEUTICS TO PROTECT AGAINST CHIKV INFECTION. WHILE A FEW VACCINE CANDIDATES HAVE PROGRESSED TO ADVANCED STAGES OF DEVELOPMENT, MANUFACTURING CHALLENGES EXIST FOR COMPLEX VACCINE COMPOSITIONS FOR ENVELOPED VIRUSES. THIS IS COMPOUNDED BY AN INCOMPLETE UNDERSTANDING OF VIRALLY-INDUCED CHRONIC CHIKV DISEASE MECHANISMS THAT CAN INTRODUCE ADVERSE EVENT RISKS, ESPECIALLY FOR REPLICATION-COMPETENT VACCINES. ALTERNATE VACCINES UTILIZING METHODS THAT CAN OFFER BETTER SAFETY PROFILES AS WELL AS BENEFITS IN MANUFACTURING ARE WARRANTED. WE HAVE DEVELOPED A PROMISING RECOMBINANT SUBUNIT CHIKV VACCINE THAT INDUCES HIGH LEVELS OF NEUTRALIZING ANTIBODIES, PREVENTS VIRAL REPLICATION IN IMMUNOCOMPETENT MICE AND PROTECTS IMMUNOCOMPROMISED MICE FROM LETHAL CHALLENGE. THE ROLE OF ANTIBODIES IN PROTECTION WAS DEMONSTRATED IN A PASSIVE TRANSFER STUDY WHERE IMMUNE SERA WAS INJECTED INTO NAIVE IMMUNOCOMPROMISED MICE AND FULL PROTECTION WAS ACHIEVED AFTER LETHAL VIRUS CHALLENGE. THE OVERALL GOAL OF THE CURRENT PHASE IIB RENEWAL RESEARCH IS TO SUPPORT PRECLINICAL EFFORTS TO FURTHER ADVANCE THE CHIKV E2/E1 RECOMBINANT SUBUNIT VACCINE CANDIDATE FORMULATED WITH THE NEXT-GENERATION ADJUVANT SLA-LSQ. THESE EFFORTS WILL ENABLE HUMAN CLINICAL TRIAL EVALUATION AND FURTHER THE POTENTIAL FOR COMMERCIALIZATION. THE PROPOSED RESEARCH AIMS TO 1) EVALUATE THE E2/E1 VACCINE IN CHRONIC DISEASE AND DURABILITY STUDIES; 2) PREPARE CGMP LOTS OF E2/E1 VACCINE ANTIGEN; 3) SUBMIT A PRE-IND PACKAGE TO FDA FOR REVIEW AND CONDUCT A RABBIT TOXICOLOGY STUDY; AND 4) PREPARE AND SUBMIT IND TO THE FDA. COMPLETION OF THE PROPOSED WORK WILL PROMOTE THE CLINICAL ADVANCEMENT OF A SAFE AND STABLE VACCINE ALTERNATIVE USING AN ESTABLISHED RECOMBINANT PROTEIN MANUFACTURING PLATFORM THAT CAN COMBAT THE SIGNIFICANT DISEASE THREAT POSED BY CHIKV.
$998.2k
11/18/24
Not listed
CHIKUNGUNYA RECOMBINANT SUBUNIT VACCINE - 7. PROJECT SUMMARY/ABSTRACT CHIKUNGUNYA VIRUS (CHIKV) IS AN ALPHAVIRUS OF THE TOGAVIRIDAE FAMILY THAT CAUSES FEVER, RASH, AND ARTHRALGIA IN HUMANS, LEADING TO DEBILITATING ILLNESS AND POOR QUALITY OF LIFE. IN THE PAST 20 YEARS, CHIKV HAS GREATLY EXPANDED ITS GEOGRAPHIC DISTRIBUTION IN PART DUE TO CLIMATE CHANGES AS WELL AS ITS ADAPTATION TO AEDES ALBOPICTUS MOSQUITOES AND REMAINS A GLOBAL HEALTH THREAT DUE TO ITS HIGH RATE OF INFECTIVITY AND THE SEVERITY OF DISEASE IT CAUSES. ESTIMATES INDICATE THAT OVER 1.3 BILLION PEOPLE RESIDE IN AREAS AT RISK FOR CHIKV TRANSMISSION, WITH OVER 114,181 CASES AND 43 DEATHS REPORTED TO DATE IN 2023 ALONE. DESPITE CHIKV'S CLASSIFICATION AS A CATEGORY C PRIORITY PATHOGEN AND ITS RECENT IDENTIFICATION AS A PROTOTYPE PATHOGEN FOR NIAID'S PLAN FOR PANDEMIC PREPAREDNESS, THERE ARE CURRENTLY NO LICENSED VACCINES OR THERAPEUTICS TO PROTECT AGAINST CHIKV INFECTION. WHILE A FEW VACCINE CANDIDATES HAVE PROGRESSED TO ADVANCED STAGES OF DEVELOPMENT, MANUFACTURING CHALLENGES EXIST FOR COMPLEX VACCINE COMPOSITIONS FOR ENVELOPED VIRUSES. THIS IS COMPOUNDED BY AN INCOMPLETE UNDERSTANDING OF VIRALLY-INDUCED CHRONIC CHIKV DISEASE MECHANISMS THAT CAN INTRODUCE ADVERSE EVENT RISKS, ESPECIALLY FOR REPLICATION-COMPETENT VACCINES. ALTERNATE VACCINES UTILIZING METHODS THAT CAN OFFER BETTER SAFETY PROFILES AS WELL AS BENEFITS IN MANUFACTURING ARE WARRANTED. WE HAVE DEVELOPED A PROMISING RECOMBINANT SUBUNIT CHIKV VACCINE THAT INDUCES HIGH LEVELS OF NEUTRALIZING ANTIBODIES, PREVENTS VIRAL REPLICATION IN IMMUNOCOMPETENT MICE AND PROTECTS IMMUNOCOMPROMISED MICE FROM LETHAL CHALLENGE. THE ROLE OF ANTIBODIES IN PROTECTION WAS DEMONSTRATED IN A PASSIVE TRANSFER STUDY WHERE IMMUNE SERA WAS INJECTED INTO NAIVE IMMUNOCOMPROMISED MICE AND FULL PROTECTION WAS ACHIEVED AFTER LETHAL VIRUS CHALLENGE. THE OVERALL GOAL OF THE CURRENT PHASE IIB RENEWAL RESEARCH IS TO SUPPORT PRECLINICAL EFFORTS TO FURTHER ADVANCE THE CHIKV E2/E1 RECOMBINANT SUBUNIT VACCINE CANDIDATE FORMULATED WITH THE NEXT-GENERATION ADJUVANT SLA-LSQ. THESE EFFORTS WILL ENABLE HUMAN CLINICAL TRIAL EVALUATION AND FURTHER THE POTENTIAL FOR COMMERCIALIZATION. THE PROPOSED RESEARCH AIMS TO 1) EVALUATE THE E2/E1 VACCINE IN CHRONIC DISEASE AND DURABILITY STUDIES; 2) PREPARE CGMP LOTS OF E2/E1 VACCINE ANTIGEN; 3) SUBMIT A PRE-IND PACKAGE TO FDA FOR REVIEW AND CONDUCT A RABBIT TOXICOLOGY STUDY; AND 4) PREPARE AND SUBMIT IND TO THE FDA. COMPLETION OF THE PROPOSED WORK WILL PROMOTE THE CLINICAL ADVANCEMENT OF A SAFE AND STABLE VACCINE ALTERNATIVE USING AN ESTABLISHED RECOMBINANT PROTEIN MANUFACTURING PLATFORM THAT CAN COMBAT THE SIGNIFICANT DISEASE THREAT POSED BY CHIKV.
$998.2k
11/18/24
Not listed
CHIKUNGUNYA RECOMBINANT SUBUNIT VACCINE - 7. PROJECT SUMMARY/ABSTRACT CHIKUNGUNYA VIRUS (CHIKV) IS AN ALPHAVIRUS OF THE TOGAVIRIDAE FAMILY THAT CAUSES FEVER, RASH, AND ARTHRALGIA IN HUMANS, LEADING TO DEBILITATING ILLNESS AND POOR QUALITY OF LIFE. IN THE PAST 20 YEARS, CHIKV HAS GREATLY EXPANDED ITS GEOGRAPHIC DISTRIBUTION IN PART DUE TO CLIMATE CHANGES AS WELL AS ITS ADAPTATION TO AEDES ALBOPICTUS MOSQUITOES AND REMAINS A GLOBAL HEALTH THREAT DUE TO ITS HIGH RATE OF INFECTIVITY AND THE SEVERITY OF DISEASE IT CAUSES. ESTIMATES INDICATE THAT OVER 1.3 BILLION PEOPLE RESIDE IN AREAS AT RISK FOR CHIKV TRANSMISSION, WITH OVER 114,181 CASES AND 43 DEATHS REPORTED TO DATE IN 2023 ALONE. DESPITE CHIKV'S CLASSIFICATION AS A CATEGORY C PRIORITY PATHOGEN AND ITS RECENT IDENTIFICATION AS A PROTOTYPE PATHOGEN FOR NIAID'S PLAN FOR PANDEMIC PREPAREDNESS, THERE ARE CURRENTLY NO LICENSED VACCINES OR THERAPEUTICS TO PROTECT AGAINST CHIKV INFECTION. WHILE A FEW VACCINE CANDIDATES HAVE PROGRESSED TO ADVANCED STAGES OF DEVELOPMENT, MANUFACTURING CHALLENGES EXIST FOR COMPLEX VACCINE COMPOSITIONS FOR ENVELOPED VIRUSES. THIS IS COMPOUNDED BY AN INCOMPLETE UNDERSTANDING OF VIRALLY-INDUCED CHRONIC CHIKV DISEASE MECHANISMS THAT CAN INTRODUCE ADVERSE EVENT RISKS, ESPECIALLY FOR REPLICATION-COMPETENT VACCINES. ALTERNATE VACCINES UTILIZING METHODS THAT CAN OFFER BETTER SAFETY PROFILES AS WELL AS BENEFITS IN MANUFACTURING ARE WARRANTED. WE HAVE DEVELOPED A PROMISING RECOMBINANT SUBUNIT CHIKV VACCINE THAT INDUCES HIGH LEVELS OF NEUTRALIZING ANTIBODIES, PREVENTS VIRAL REPLICATION IN IMMUNOCOMPETENT MICE AND PROTECTS IMMUNOCOMPROMISED MICE FROM LETHAL CHALLENGE. THE ROLE OF ANTIBODIES IN PROTECTION WAS DEMONSTRATED IN A PASSIVE TRANSFER STUDY WHERE IMMUNE SERA WAS INJECTED INTO NAIVE IMMUNOCOMPROMISED MICE AND FULL PROTECTION WAS ACHIEVED AFTER LETHAL VIRUS CHALLENGE. THE OVERALL GOAL OF THE CURRENT PHASE IIB RENEWAL RESEARCH IS TO SUPPORT PRECLINICAL EFFORTS TO FURTHER ADVANCE THE CHIKV E2/E1 RECOMBINANT SUBUNIT VACCINE CANDIDATE FORMULATED WITH THE NEXT-GENERATION ADJUVANT SLA-LSQ. THESE EFFORTS WILL ENABLE HUMAN CLINICAL TRIAL EVALUATION AND FURTHER THE POTENTIAL FOR COMMERCIALIZATION. THE PROPOSED RESEARCH AIMS TO 1) EVALUATE THE E2/E1 VACCINE IN CHRONIC DISEASE AND DURABILITY STUDIES; 2) PREPARE CGMP LOTS OF E2/E1 VACCINE ANTIGEN; 3) SUBMIT A PRE-IND PACKAGE TO FDA FOR REVIEW AND CONDUCT A RABBIT TOXICOLOGY STUDY; AND 4) PREPARE AND SUBMIT IND TO THE FDA. COMPLETION OF THE PROPOSED WORK WILL PROMOTE THE CLINICAL ADVANCEMENT OF A SAFE AND STABLE VACCINE ALTERNATIVE USING AN ESTABLISHED RECOMBINANT PROTEIN MANUFACTURING PLATFORM THAT CAN COMBAT THE SIGNIFICANT DISEASE THREAT POSED BY CHIKV.
$0
6/10/24
Not listed
CHIKUNGUNYA RECOMBINANT SUBUNIT VACCINE - 7. PROJECT SUMMARY/ABSTRACT CHIKUNGUNYA VIRUS (CHIKV) IS AN ALPHAVIRUS OF THE TOGAVIRIDAE FAMILY THAT CAUSES FEVER, RASH, AND ARTHRALGIA IN HUMANS, LEADING TO DEBILITATING ILLNESS AND POOR QUALITY OF LIFE. IN THE PAST 20 YEARS, CHIKV HAS GREATLY EXPANDED ITS GEOGRAPHIC DISTRIBUTION IN PART DUE TO CLIMATE CHANGES AS WELL AS ITS ADAPTATION TO AEDES ALBOPICTUS MOSQUITOES AND REMAINS A GLOBAL HEALTH THREAT DUE TO ITS HIGH RATE OF INFECTIVITY AND THE SEVERITY OF DISEASE IT CAUSES. ESTIMATES INDICATE THAT OVER 1.3 BILLION PEOPLE RESIDE IN AREAS AT RISK FOR CHIKV TRANSMISSION, WITH OVER 114,181 CASES AND 43 DEATHS REPORTED TO DATE IN 2023 ALONE. DESPITE CHIKV'S CLASSIFICATION AS A CATEGORY C PRIORITY PATHOGEN AND ITS RECENT IDENTIFICATION AS A PROTOTYPE PATHOGEN FOR NIAID'S PLAN FOR PANDEMIC PREPAREDNESS, THERE ARE CURRENTLY NO LICENSED VACCINES OR THERAPEUTICS TO PROTECT AGAINST CHIKV INFECTION. WHILE A FEW VACCINE CANDIDATES HAVE PROGRESSED TO ADVANCED STAGES OF DEVELOPMENT, MANUFACTURING CHALLENGES EXIST FOR COMPLEX VACCINE COMPOSITIONS FOR ENVELOPED VIRUSES. THIS IS COMPOUNDED BY AN INCOMPLETE UNDERSTANDING OF VIRALLY-INDUCED CHRONIC CHIKV DISEASE MECHANISMS THAT CAN INTRODUCE ADVERSE EVENT RISKS, ESPECIALLY FOR REPLICATION-COMPETENT VACCINES. ALTERNATE VACCINES UTILIZING METHODS THAT CAN OFFER BETTER SAFETY PROFILES AS WELL AS BENEFITS IN MANUFACTURING ARE WARRANTED. WE HAVE DEVELOPED A PROMISING RECOMBINANT SUBUNIT CHIKV VACCINE THAT INDUCES HIGH LEVELS OF NEUTRALIZING ANTIBODIES, PREVENTS VIRAL REPLICATION IN IMMUNOCOMPETENT MICE AND PROTECTS IMMUNOCOMPROMISED MICE FROM LETHAL CHALLENGE. THE ROLE OF ANTIBODIES IN PROTECTION WAS DEMONSTRATED IN A PASSIVE TRANSFER STUDY WHERE IMMUNE SERA WAS INJECTED INTO NAIVE IMMUNOCOMPROMISED MICE AND FULL PROTECTION WAS ACHIEVED AFTER LETHAL VIRUS CHALLENGE. THE OVERALL GOAL OF THE CURRENT PHASE IIB RENEWAL RESEARCH IS TO SUPPORT PRECLINICAL EFFORTS TO FURTHER ADVANCE THE CHIKV E2/E1 RECOMBINANT SUBUNIT VACCINE CANDIDATE FORMULATED WITH THE NEXT-GENERATION ADJUVANT SLA-LSQ. THESE EFFORTS WILL ENABLE HUMAN CLINICAL TRIAL EVALUATION AND FURTHER THE POTENTIAL FOR COMMERCIALIZATION. THE PROPOSED RESEARCH AIMS TO 1) EVALUATE THE E2/E1 VACCINE IN CHRONIC DISEASE AND DURABILITY STUDIES; 2) PREPARE CGMP LOTS OF E2/E1 VACCINE ANTIGEN; 3) SUBMIT A PRE-IND PACKAGE TO FDA FOR REVIEW AND CONDUCT A RABBIT TOXICOLOGY STUDY; AND 4) PREPARE AND SUBMIT IND TO THE FDA. COMPLETION OF THE PROPOSED WORK WILL PROMOTE THE CLINICAL ADVANCEMENT OF A SAFE AND STABLE VACCINE ALTERNATIVE USING AN ESTABLISHED RECOMBINANT PROTEIN MANUFACTURING PLATFORM THAT CAN COMBAT THE SIGNIFICANT DISEASE THREAT POSED BY CHIKV.
$0
6/10/24